clinical trial · NCT06144697
A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants
Bristol-Myers Squibb·phase1·terminated·n = 267
Healthy ParticipantsBMS-986465PlaceboPegasysFamotidine
brief summary
The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy participants of Japanese ethnicity.
started
Jan 29, 2024
primary completion
Oct 16, 2024
completion
Oct 16, 2024
last updated
Feb 6, 2025
official title
A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Prodrug BMS-986465 and Its Active Derivative, BMS-986464, in Healthy Participants Including Healthy Participants of Japanese Ethnicity and an Open-label Assessment of Food, Formulation, and pH Effects on the Relative Bioavailability of BMS-986465 and BMS-986464
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol